researc-dev1

Research & Development

Sanofi Pasteur MSD is proud to be able to draw from two world leading pipelines for its vaccine development and delivery.

  • Sanofi Pasteur MSD Pipeline

    R&D Key developments Registration New Vaccines

    Vaxigrip quadrivalent

    9 valent HPV vaccine (V503)

    Pediatric Hexavalent Vaccine (PR5i)

    ProQuad

    Hexyon (2013)

    Zostavax (2013)

    Sanofi Pasteur pipeline

    Merck pipeline

    Joint Sanofi Pasteur/Merck development

  • Sanofi Pasteur R&D Pipeline

    Phase I Phase II Phase III Submitted

    Tuberculosis

    Recombinant subunit vaccine

    Herpes Simplex Virus Type 2

    HSV-2 vaccine

    Streptococcus pneumonia

    Meningitis & pneumonia vaccine

    Pseudomonas aeruginosa

    Antibody fragment product. Prevention of ventilator-associated pneumonia

    Meningitis ACYW conj

    2nd generation meningococcal conjugate infant vaccine

    Rabies VRVg

    Purified vero rabies vaccine

    Rotavirus

    Live Attenuated Tetravalent Rotavirus oral vaccine

    Quadracel

    Diphteria, tetanus & pertussis polio 4-6 years of age

    DTP-HepB-Polio Hib (PR5I)

    Pediatric hexavalent vaccine

    Dengue

    Mid-to-severe dengue fever vaccine

    Fluzone® QIV ID (U.S.A)

    Quadrivalent inactivated influenza vaccine Intradermal

    Clostridium difficile

    Toxoid vaccine

    Vaxigrip® QIV IM

    Quandrivalent inactivated influenza vaccine

  • Merck R&D Pipeline

    Phase 2 Phase 3 Registration

    Pneumoconjugate vaccine

    v114

    Cervical cancer & other HPV-related diseases

    9-type HPV vaccine V503

    Pediatric hexavalent vaccine DTP-HepB-Polio-Hib

    V419

    Shingles (Herpes Zoster) Inactivated VZV vaccine

    V212

  • Sanofi Pasteur MSD pipeline
  • Sanofi Pasteur R&D Portfolio
  • Merck R&D Portfolio